Protalix is leveraging the ProCellEx production system to develop novel, next-generation (biobetter) and biosimilar protein-based therapeutics, both independently and through strategic partnerships with biopharmaceutical companies. ProCellEx potentially offers significant advantages over existing expression systems, including cost effectiveness, safety, and entry into certain patent-protected markets.
Protalix is interested in considering partnership opportunities surrounding the ProCellEx technology, as well as for its proprietary therapeutic protein product candidates.
For partnership inquiries:
Protalix maintains strategically important partnerships with several world-renowned pharmaceutical companies and leading scientific institutions.
In December 2009, Protalix entered into an agreement with Pfizer Inc. to develop and commercialize taliglucerase alfa, a plant cell-expressed form of the glucocerebrosidase (GCD) enzyme. Under the terms of the agreement, Pfizer has exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while Protalix retained the exclusive commercialization rights in Israel.
Protalix has received $98.3 million, in the aggregate, as milestone payments under the agreement. In addition, the May 2012 approval by the FDA of ELELYSO™ (taliglucerase alfa) triggered a $25 million milestone payment to Protalix from Pfizer. Protalix is eligible to receive additional regulatory milestone payments of up to $25 million. In the countries where Pfizer holds commercial rights, Pfizer and Protalix will share revenues and expenses, subject to certain exceptions, for the development and commercialization of taliglucerase alfa on a 60 percent/40 percent basis, respectively.
Additional regulatory submissions are in progress elsewhere throughout the world.
In September 2006, Protalix entered into a collaboration and licensing agreement with Teva surrounding the research and development of proteins utilizing Protalix's ProCellEx protein expression system.
In March 2006, Protalix entered into a research and license agreement with the Yeda Research and Development Company Limited, the technology transfer arm of the Weizmann Institute of Science. Under the terms of the agreement, Yeda is designing a next-generation version of glucocerebrosidase for the treatment of Gaucher disease that can be expressed using Protalix’s ProCellEx protein expression system. Yeda has granted Protalix a license to use its technology and discoveries to support the development, production and sale of enzymatically active mutations of GCD and derivatives thereof for the treatment of Gaucher disease. Protalix is responsible for commercializing the products developed under the license. Under the agreement, Protalix will pay certain minimum royalty amounts and varying fixed royalty amounts on net sales of products developed using the licensed technology for the treatment of Gaucher disease and other indications, as well as for sublicensing revenues.
In January 2007, Protalix entered into an agreement with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem, Israel, and with the Boyce Thompson Institute, Inc., which is affiliated with Cornell University. These agreements support the development of a proprietary plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program. Pursuant to the terms of the agreement, Protalix licensed the technology underlying the developed acetylcholinesterase from Yissum Research/Hebrew University and Boyce Thompson.